脓毒症基础研究——进展与挑战  

Basic research in sepsis:advances and challenges

作　　者：吴淼[1] 白镓玮 严颜 解鑫宇 马承泰 杜贤进[1,2] Wu Miao;Bai Jiawei;Yan Yan;Xie Xinyu;Ma Chengtai;Du Xianjin(Department of Emergency,Renmin Hospital of Wuhan University,Wuhan 430060,Hubei,China;Department of Critical Care Medicine,Renmin Hospital of Wuhan University,Wuhan 430060,Hubei,China)

机构地区：[1]武汉大学人民医院急诊科,湖北武汉430060 [2]武汉大学人民医院重症医学科,湖北武汉430060

出　　处：《中华危重病急救医学》2024年第6期561-566,共6页Chinese Critical Care Medicine

基　　金：国家自然科学基金(82202409,82372179);湖北省自然科学基金(2022CFA089)。

摘　　要：虽然人们对脓毒症的认知从"脓毒症1.0"提高到了"脓毒症3.0",脓毒症的临床管理共识也不断更新,但脓毒症的发病率和病死率仍居高不下。因此,深入探明脓毒症发病机制和相关影响因素,对于揭示脓毒症本质、改善脓毒症患者的临床结局具有重要意义。本文将聚焦脓毒症基础研究中的关键问题,并就脓毒症基础研究的新进展及面临的挑战进行概述,主要包括基因多态性、微生物、高迁移率族蛋白B1(HMGB1)、内皮功能障碍、免疫治疗及生物标志物等方面,以期为脓毒症的诊断和治疗提供新思路。Although the understanding of sepsis has evolved from"sepsis 1.0"to"sepsis 3.0",and the consensus on clinical management of sepsis has been continuously updated,the incidence rate and mortality of sepsis remain high.Therefore,in-depth investigation of the pathogenesis and related influencing factors of sepsis is of great significance for revealing the nature of sepsis and improving the clinical outcome of sepsis patients.This review will focus on the key issues in the basic research of sepsis,and summarize the recent advances and challenges in this field,mainly including genetic polymorphism,microorganisms,high-mobility group box 1(HMGB1),endothelial dysfunction,immunotherapy,and biomarkers,aiming to provide new insights for the diagnosis and treatment of sepsis.

关 键 词：脓毒症 基因多态性 微生物 内皮功能障碍 免疫治疗 生物标志物 

分 类 号：R459.7[医药卫生—急诊医学]